Skip to search formSkip to main contentSkip to account menu

Casodex

Known as: AstraZeneca brand of bicalutamide, Zeneca brand of bicalutamide, Astra brand of bicalutamide 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2013
Highly Cited
2013
Background: Androgen deprivation therapy (ADT) suppresses prostate cancer (PCa) growth, yet its effects on PCa metastasis remain… 
Highly Cited
2010
Highly Cited
2010
Highly Cited
2000
Highly Cited
2000
An expression construct containing the cDNA encoding a modified aequorea green fluorescent protein (GFP) ligated to the 5'-end of… 
Highly Cited
1999
Highly Cited
1999
Androgens are important growth regulators in prostate cancer. Their known mode of action in target cells requires binding to a… 
Highly Cited
1998
Highly Cited
1998
Objectives: To evaluate the efficacy and tolerability of ‘Casodex’TM monotherapy (150 mg daily) for metastatic and locally… 
Highly Cited
1996
Highly Cited
1996
Aberrant activation of the androgen receptor through signaling pathways independent of androgen may be responsible for the… 
Highly Cited
1995
Highly Cited
1995
Aberrant activation of the androgen receptor (AR) may be one of the mechanisms which contribute to progression of prostatic… 
Highly Cited
1994
Highly Cited
1994
Aberrant activation of the androgen receptor (AR) may be one of the mechanisms which contribute to progression of prostatic… 
Highly Cited
1994
Highly Cited
1994
OBJECTIVE Casodex (Zeneca) is a new potent, long‐acting non‐steroidal anti‐androgen, which produces androgen deprivation by…